Analyst Consensus ?
ConsensusBuy15 ratings
Bullish853.3%
Neutral746.7%
Bearish00.0%
Ingersoll Rand Inc. · IR · FY2024 Q2 · Calendar Q3 2024
Ingersoll Rand raises 2024 outlook as biopharma and services support growth
The current analysis supports a constructive but conditional view: Ingersoll Rand's raised outlook is supported by compressor demand, biopharma exposure, service expansion and acquisition contributions. The case is tempered by modest expected organic growth in the second half, China weakness, project timing and integration execution.
Reported After market closeNYSEIndustrials
$30.18B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.83
Consensus $0.78
EPS surprise
+6.1%
Reported versus consensus
Reported revenue
$1.81B
Consensus $1.80B
Revenue surprise
+0.3%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-9.1%
Event window
SPY move
-1.4%
Same window
Abnormal move
-7.7%
Stock minus SPY
Volume
3.4×
Versus trailing sessions
Subsequent drift
-0.5%
Up to 20 sessions
IRSPY benchmark
Ask FN2 about IR FY2024 Q2
Transcript, numbers and history already loaded
Why did IR fall 9.1% after beating EPS estimates in FY2024 Q2?What changed in IR's guidance and outlook in FY2024 Q2?Give me the bull and bear case for IR after FY2024 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current analysis shows stronger reported Q2 performance, higher full-year revenue-growth guidance, and greater emphasis on acquisition-led revenue and biopharma growth. The risk picture also shifted toward a softer China outlook, longer project cycles and integration execution.
Guidance delta
Raised: full-year 2024 guidance moved from 4%-6% revenue growth in the prior analysis to 6%-8% in the current analysis, with approximately 14% EBITDA growth highlighted.
Key takeaways
- Q2 delivered record performance, with adjusted EBITDA margin up 220 basis points.
- Management raised full-year 2024 guidance to 6%-8% revenue growth and approximately 14% EBITDA growth.
- Biopharma demand, compressor activity, service expansion and bolt-on acquisitions remain key growth drivers.
- Organic second-half growth is expected to be modest at 0%-2%, reflecting a softer China outlook and longer project cycles.
Management priorities
- Execute the IRX operational-efficiency program.
- Pursue bolt-on acquisitions targeting mid-teens ROIC.
- Expand service contracts and EcoPlant offerings globally.
- Invest in biopharma single-use technologies, demand generation and sales-force expansion.
Follow IR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$77.78Current
$50Low
$77.25Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 18, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | In Line | In Line | Maintain | Aug 11, 2026 |
| Baird | Outperform | Outperform | Maintain | Aug 3, 2026 |
| Stifel | Hold | Hold | Maintain | Jul 20, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jun 3, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Citigroup | Buy | Buy | Maintain | Apr 30, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Dec 12, 2024 |
| CFRA | Hold | Hold | Maintain | Aug 2, 2024 |
| UBS | Buy | Buy | Maintain | Jan 29, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 12, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 4, 2022 |
| Jefferies | Buy | Buy | Maintain | Jul 15, 2022 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Apr 6, 2022 |
| Vertical Research | Buy | Hold | Upgrade | Jun 17, 2021 |
Named analyst price targets
Upside is calculated against the persisted current price $77.78. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Christopher Snyder | $87 | $87 | +11.9% | Aug 10, 2026 |
| Stifel Nicolaus | Analyst unavailable | $84 | $82.24 | +8.0% | Jul 20, 2026 |
| Morgan Stanley | Christopher Snyder | $80 | $71.7 | +2.9% | Jun 3, 2026 |
| Evercore ISI | David Raso | $84 | $75.31 | +8.0% | May 11, 2026 |
| Robert W. Baird | Analyst unavailable | $103 | $77.46 | +32.4% | Apr 30, 2026 |
| Barclays | Analyst unavailable | $95 | $77.46 | +22.1% | Apr 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $90 | $87.69 | +15.7% | Apr 14, 2026 |
| Robert W. Baird | Analyst unavailable | $115 | $98.52 | +47.9% | Feb 17, 2026 |
| Barclays | Analyst unavailable | $111 | $98.52 | +42.7% | Feb 17, 2026 |
| Wells Fargo | Joseph O'Dea | $110 | $98.52 | +41.4% | Feb 17, 2026 |
| Stifel Nicolaus | Nathan Jones | $87 | $87.27 | +11.9% | Jan 23, 2026 |
| Wells Fargo | Joseph O'Dea | $92 | $83.43 | +18.3% | Jan 7, 2026 |
| Stifel Nicolaus | Analyst unavailable | $81 | $79.88 | +4.1% | Dec 16, 2025 |
| Robert W. Baird | Analyst unavailable | $100 | $76.33 | +28.6% | Nov 3, 2025 |
| Stifel Nicolaus | Analyst unavailable | $79 | $77.22 | +1.6% | Oct 20, 2025 |
| Stifel Nicolaus | Analyst unavailable | $78 | $78.6 | +0.3% | Aug 4, 2025 |
| Melius Research | Rob Wertheimer | $93 | $89.02 | +19.6% | Jul 14, 2025 |
| Stifel Nicolaus | Nathan Jones | $77 | $73.37 | -1.0% | Apr 14, 2025 |
| Barclays | Julian Mitchell | $93 | $81.38 | +19.6% | Mar 26, 2025 |
| Barclays | Analyst unavailable | $96 | $85.22 | +23.4% | Mar 10, 2025 |
| Barclays | Julian Mitchell | $115 | $89.16 | +47.9% | Jan 8, 2025 |
| Wells Fargo | Joseph O'Dea | $105 | $89.16 | +35.0% | Jan 7, 2025 |
| Barclays | Julian Mitchell | $105 | $98 | +35.0% | Oct 2, 2024 |
| Morgan Stanley | Chris Snyder | $97 | $87.61 | +24.7% | Sep 6, 2024 |
| Stifel Nicolaus | Nathan Jones | $101 | $87.76 | +29.9% | Aug 2, 2024 |
| Barclays | Julian Mitchell | $101 | $91.23 | +29.9% | Aug 2, 2024 |
| Robert W. Baird | Michael Halloran | $109 | $86.72 | +40.1% | May 6, 2024 |
| Wells Fargo | Analyst unavailable | $60 | $53.22 | -22.9% | Jan 5, 2023 |
| Barclays | Analyst unavailable | $60 | $53.41 | -22.9% | Jan 5, 2023 |
| Jefferies | Stephen Volkmann | $55 | $44.55 | -29.3% | Jul 26, 2022 |
| Deutsche Bank | Analyst unavailable | $50 | $41.04 | -35.7% | Jul 13, 2022 |
| Goldman Sachs | Analyst unavailable | $50 | $41.76 | -35.7% | Jun 23, 2022 |
| Morgan Stanley | Joshua Pokrzywinski | $52 | $49.33 | -33.1% | Jun 7, 2022 |
| Credit Suisse | Analyst unavailable | $52 | $43.8 | -33.1% | May 6, 2022 |
| Goldman Sachs | Joe Ritchie | $68 | $57.1 | -12.6% | Nov 4, 2021 |
| Citigroup | Andrew Kaplowitz | $62 | $52.9 | -20.3% | Sep 3, 2021 |
| Vertical Research | Jeffrey Sprague | $54 | $45.95 | -30.6% | Jun 17, 2021 |
| Evercore ISI | David Raso | $53 | $47.09 | -31.9% | May 12, 2021 |
Track every rating change on IR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIngersoll Rand Inc., established in 1859 and headquartered in Davidson, North Carolina, delivers essential air, fluid, energy, medical, and specialized vehicle technologies to customers across the United States, Europe, the Middle East, Africa, and the Asia Pacific regions. The company operates through two primary divisions: Industrial Technologies and Services, and Precision and Science Technologies. The Industrial Technologies and Services division is responsible for the design, production, sales, and maintenance of various air and gas compression, vacuum, and blower solutions, alongside fluid handling and loading systems, power tools, and lifting apparatus. This segment also encompasses all related spare parts, consumables, air purification systems, controls, additional accessories, and support services.…
Historical context
All IR earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| JBHT J.B. Hunt Transport Services, Inc. | FY2026 Q3 · Calendar Q4 2026 | +0.6% | -2.0% | J.B. Hunt: Strong demand, but margin repair remains central |
| FAST Fastenal Company | FY2026 Q3 · Calendar Q4 2026 | +3.3% | +1.1% | Fastenal Q3: Share Gains and Digital Adoption Lift Growth |
Latest beats and misses
Who reports nextBeat on EPS
Get the IR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-18T18:20:41.934283+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-18T18:20:41.930554+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-18. For educational purposes only; not investment advice.